Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 13/20 | 0.79 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | CLK1 | P49759 | 1/20 | 0.43 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.42 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1592023 | 1.00 | P2RX7 (0.79) | P2RX7KDM4EMAPTCLK1TRPV1 | |
| SCHEMBL1590173 | 1.00 | P2RX7 (0.79) | P2RX7KDM4EMAPTCLK1TRPV1 | |
| SCHEMBL1590347 | 0.93 | P2RX7 (0.76) | P2RX7KDM4EMAPTCLK1TRPV1 | |
| SCHEMBL1590848 | 0.93 | P2RX7 (0.76) | P2RX7KDM4EMAPTCLK1TRPV1 | |
| SCHEMBL1590495 | 0.92 | P2RX7 (0.80) | P2RX7KDM4EMAPTCLK1TRPV1 | |
| SCHEMBL1591221 | 0.92 | P2RX7 (0.80) | P2RX7KDM4EMAPTCLK1TRPV1 | |
| SCHEMBL1591210 | 0.92 | P2RX7 (0.80) | P2RX7KDM4EMAPTCLK1TRPV1 | |
| SCHEMBL1591078 | 0.88 | P2RX7 (1.00) | P2RX7KDM4EMAPTCLK1TRPV1 | |
| SCHEMBL1590639 | 0.88 | P2RX7 (0.62) | P2RX7KDM4EMAPTCLK1TRPV1 | |
| SCHEMBL1590644 | 0.88 | P2RX7 (0.62) | P2RX7KDM4EMAPTCLK1TRPV1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1933622-B1 | BICYCLOHETEROARYL COMPOUNDS AS P2X7 MODULATORS AND USES THEREOF | SECOND GENOME INC (US) | 2016-03-09 | — | — | EP | disclosed |
| US-20110092476-A1 | Bicycloheteroaryl compounds as P2X7 modulators and uses thereof | RENOVIS, INC. | 2011-04-21 | — | — | US | disclosed |
| US-7816371-B2 | Bicycloheteroaryl compounds as P2X7 modulators and uses thereof | RENOVIS, INC. (US) | 2010-10-19 | — | — | US | disclosed |
| CN-101442909-A | Bicycloheteroaryl compounds as P2X7 modulators and uses thereof | RENOVIS INC (US) | 2009-05-27 | — | — | CN | disclosed |
| US-20070225324-A1 | Bicycloheteroaryl compounds as P2X7 modulators and uses thereof | SECOND GENOME, INC. | 2007-09-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070225324-A1 | Bicycloheteroaryl compounds as P2X7 modulators and uses thereof | P2RX7, P2RX3, P2RX2 | P2RX7 1/4885KDM4E 4128/4885MAPT 4477/4885 |
| US-20110092476-A1 | Bicycloheteroaryl compounds as P2X7 modulators and uses thereof | P2RX7, P2RX3, P2RX2 | P2RX7 1/4885KDM4E 4128/4885MAPT 4477/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.